Celltrion sets up Chinese JV and eyes manufacturing facility in country

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Rawpixel)
(Image: Getty/Rawpixel)

Related tags: Celltrion, Nan Fung Group, Vcell Healthcare, China

Celltrion has partnered with Nan Fung Group to create Vcell Healthcare, which will manufacture and commercialize three of Celltrion’s biosimilar products in China.

As part of the joint venture, Celltrion will provide Vcell with exclusive rights in mainland China to its three US and European Union (EU) approved biosimilars: CT-P13 (Remsima), CT-P10 (Truxima), and CT-P6 (Herzuma).

The three biosimilars are Celltrion’s versions of Remicade (infliximab), MabThera (rituximab), and Herceptin (trastuzumab), respectively.

According to a statement, the newly established biopharma company will seek regulatory approval in China and will look to launch ‘expeditiously’. Whilst this process is ongoing, the partnership will look to establish a ‘world-class biologics manufacturing facility’ in China.

As well as providing the manufacture for Vcell’s portfolio of biosimilars, it was also suggested that the facility could be used to provide contract development and manufacturing organization (CDMO) capabilities.

Antony Leung, CEO of Nan Fung Group, said, “China has huge unmet medical needs for high quality drugs with affordable prices. We hope Vcell Healthcare could bring world-class biosimilar products to benefit Chinese patients and establish a state-of-the-art manufacturing base in China to serve the growing demand for high quality CDMO [services] in the country.”

Celltrion’s chairman, Seo Jung-Jin, suggested that the joint venture will serve as the ‘cornerstone’ for the company’s entry into the Chinese market.

The move is part of a wider plan the company has to rapidly expand​ its business moving towards 2030, which sees the South Korean company aiming to develop one million liters of capacity for the production of biologics across its global production sites.

Related news

Show more

Related products

show more

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us


View more